Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

European Journal of Cancer

Volumn 48, Issue 7, 2012, Pages 1031-1037

  Keizman, Daniel ^a   Ish Shalom, Maya ^a   Pili, Roberto ^b   Hammers, Hans ^c   Eisenberger, Mario A ^c   Sinibaldi, Victoria ^c   Boursi, Ben ^d   Maimon, Natalie ^a   Gottfried, Maya ^a   Hayat, Henry ^e   Peer, Avivit ^f   Kovel, Svetlana ^g   Sella, Avishay ^g   Berger, Raanan ^d   Carducci, Michael A ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e WOLFSON MEDICAL CENTER   (Israel)

^f RAMBAM MEDICAL CENTER   (Israel)

^g Asaf Harofe Medical Center   (Israel)

Author keywords

Bisphosphonates; Bone metastases; Outcome; Renal cell carcinoma; Sunitinib

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; SUNITINIB; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859516073     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.050     Document Type: Article

References (23)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. J.S. Lam, J.T. Leppert, A.S. Belldegrun, and R.A. Figlin Novel approaches in the therapy of metastatic renal cell carcinoma World J Urol 23 2005 202 212
3. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
4. N.K. Janzen, H.L. Kim, R.A. Figlin, and A.S. Belldegrun Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852
5. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma NEJM 356 2007 115 124
6. E. Woodward, S. Jagdev, and L. McParland Skeletal complications and survival in renal cancer patients with bone metastases Bone 48 2011 160 166
7. B. Beuselinck, S. Oudard, and O. Rixe Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib Ann Oncol 22 2011 794 800
8. F. Saad, and J.A. Eastham Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer Semin Oncol 37 Suppl 1 2010 S38 S44 [Review]
9. A. Ullen, S. Schwarz, and L. Lennartsson Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines Scand J Urol Nephrol 43 2009 98 103
10. J. Soltau, U. Zirrgiebel, and N. Esser Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model Anticancer Res 28 2008 933 941
11. H. Pandha, L. Birchall, and B. Meyer Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines J Urol 176 2006 2255 2261
12. A. Lipton, M. Zheng, and J. Seaman Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 2003 962 969
13. B.L. Beuselinck, J. Medioni, and P. Wolter Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib J Clin Oncol 29 suppl 7 2011 abstr 388
14. C. Sahi, J.J. Knox, M. Clemons, A.M. Joshua, and R. Broom Renal cell carcinoma bone metastases: clinical advances Ther Adv Med Oncol 2 2010 75 83
15. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
16. S. Patil, R.A. Figlin, and T.E. Hutson Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 2011 295 300
17. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
18. T.K. Choueiri, A. Plantade, and P. Elson Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
19. B.I. Rini, D.P. Cohen, and D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
20. D.Y. Heng, W. Xie, and M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
21. D. Keizman, P. Huang, and M.A. Eisenberger Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination Eur J Cancer 47 2011 1955 1961
22. D. Keizman, M. Ish-Shalom, and P. Huang The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma Eur J Cancer 2011 [Epub ahead of print]
23. J.R. Berenson Antitumor effects of bisphosphonates: from the laboratory to the clinic Curr Opin Support Palliat Care 5 2011 233 240